Sandra Calvin, SVP, CHIEF ACCOUNTING OFFICER at Travere Therapeutics, Inc. (TVTX), sold 5,375 shares at $62.13 ($335K) on 2026-09-15, disclosed to the SEC on 2026-09-17.
Scheduled sale ($335k) by SVP, CHIEF ACCOUNTING OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $62.13 | 4,275 | $266K | 79.3% |
| 2 | $62.85 | 800 | $50K | 15.0% |
| 3 | $63.66 | 300 | $19K | 5.7% |
| Total | $62.33 avg | 5,375 | $335K | 100% |
| Filing → |
| TVTX | SELL | 2025-12-29 | $296K | — | Filing → |
| TVTX | SELL | 2025-12-16 | $105K | — | Filing → |
| TVTX | SELL | 2025-11-06 | $2.4M | — | Filing → |